Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: A special reference to classification and predictive factors

Sun Och Yoon, Baek Hui Kim, Hye Seung Lee, Gyeong Hoon Kang, Woo Ho Kim, Young A. Kim, Je Eun Kim, Mee Soo Chang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, Β-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-B, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (P0.05), including Β-catenin (13% in mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31 vs 67%), NF-B (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and MUC5AC (3 vs 40%). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (P0.05). Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (P0.05; mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (P0.05, both). NF-B status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also Β-catenin loss, on overall survival of patients. In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and more altered protein markers, p53 overexpression, NF-B positivity, and Β-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.

Original languageEnglish
Pages (from-to)1102-1112
Number of pages11
JournalModern Pathology
Volume22
Issue number8
DOIs
Publication statusPublished - 2009 Aug 1

Fingerprint

Appendiceal Neoplasms
Mucinous Adenocarcinoma
Adenoma
Catenins
Proteins
Neoplasms
Cadherins
Vascular Endothelial Growth Factor A
Disease-Free Survival
Cyclin-Dependent Kinase Inhibitor p21
Survival
Cyclin D1
Mucins
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Yoon, Sun Och ; Kim, Baek Hui ; Lee, Hye Seung ; Kang, Gyeong Hoon ; Kim, Woo Ho ; Kim, Young A. ; Kim, Je Eun ; Chang, Mee Soo. / Differential protein immunoexpression profiles in appendiceal mucinous neoplasms : A special reference to classification and predictive factors. In: Modern Pathology. 2009 ; Vol. 22, No. 8. pp. 1102-1112.
@article{549aec9069f74b1a8c1ed81f6be8de2b,
title = "Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: A special reference to classification and predictive factors",
abstract = "Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, Β-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-B, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (P0.05), including Β-catenin (13{\%} in mucinous adenoma vs 60{\%} in mucinous adenocarcinoma), CyclinD1 (44 vs 87{\%}), Ki-67 (high labeling index: 31 vs 67{\%}), NF-B (19 vs 60{\%}), VEGF (16 vs 87{\%}), E-cadherin (0 vs 47{\%}), p53 (6 vs 40{\%}), MUC2 (9 vs 67{\%}), and MUC5AC (3 vs 40{\%}). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (P0.05). Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (P0.05; mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (P0.05, both). NF-B status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also Β-catenin loss, on overall survival of patients. In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and more altered protein markers, p53 overexpression, NF-B positivity, and Β-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.",
author = "Yoon, {Sun Och} and Kim, {Baek Hui} and Lee, {Hye Seung} and Kang, {Gyeong Hoon} and Kim, {Woo Ho} and Kim, {Young A.} and Kim, {Je Eun} and Chang, {Mee Soo}",
year = "2009",
month = "8",
day = "1",
doi = "10.1038/modpathol.2009.74",
language = "English",
volume = "22",
pages = "1102--1112",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

Differential protein immunoexpression profiles in appendiceal mucinous neoplasms : A special reference to classification and predictive factors. / Yoon, Sun Och; Kim, Baek Hui; Lee, Hye Seung; Kang, Gyeong Hoon; Kim, Woo Ho; Kim, Young A.; Kim, Je Eun; Chang, Mee Soo.

In: Modern Pathology, Vol. 22, No. 8, 01.08.2009, p. 1102-1112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential protein immunoexpression profiles in appendiceal mucinous neoplasms

T2 - A special reference to classification and predictive factors

AU - Yoon, Sun Och

AU - Kim, Baek Hui

AU - Lee, Hye Seung

AU - Kang, Gyeong Hoon

AU - Kim, Woo Ho

AU - Kim, Young A.

AU - Kim, Je Eun

AU - Chang, Mee Soo

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, Β-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-B, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (P0.05), including Β-catenin (13% in mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31 vs 67%), NF-B (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and MUC5AC (3 vs 40%). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (P0.05). Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (P0.05; mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (P0.05, both). NF-B status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also Β-catenin loss, on overall survival of patients. In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and more altered protein markers, p53 overexpression, NF-B positivity, and Β-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.

AB - Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, Β-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-B, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (P0.05), including Β-catenin (13% in mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31 vs 67%), NF-B (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and MUC5AC (3 vs 40%). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (P0.05). Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (P0.05; mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (P0.05, both). NF-B status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also Β-catenin loss, on overall survival of patients. In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and more altered protein markers, p53 overexpression, NF-B positivity, and Β-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.

UR - http://www.scopus.com/inward/record.url?scp=68249087325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249087325&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.74

DO - 10.1038/modpathol.2009.74

M3 - Article

C2 - 19448592

AN - SCOPUS:68249087325

VL - 22

SP - 1102

EP - 1112

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -